drugset / Trial / NCT01741142

Efficacy and Safety Study of ABT-436 in Major Depressive Disorder

NCT01741142

Phase 2 Terminated 19 enrolled AbbVie
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose is to study the efficacy and safety of ABT-436 in Major Depressive Disorder.

Timeline

Start
2012-01
Primary completion
2013-10
Completion
2015-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ABT-436 Unknown
Comparator Escitalopram Small molecule